Emerging therapies for fibromyalgia: an update

Bibliography

• Crofford LJ, Clauw DJ. Fibromyalgia: where are we a decade after the American College of Rheumatology classification criteria were developed? Arthritis Rheum 2002;46(5):1136-8
   PubMed Web of Science ®Google Scholar
• Hadler NM. “Fibromyalgia” and the medicalization of misery. J Rheumatol 2003;30(8):1668-70
   PubMed Web of Science ®Google Scholar
• Wolfe F. Fibromyalgianess. Arthritis Rheum 2009;61(6):715-6
   PubMed Web of Science ®Google Scholar
• Chang PF, Arendt-Nielsen L, Graven-Nielsen T, Chen AC. Psychophysical and EEG responses to repeated experimental muscle pain in humans: pain intensity encodes EEG activity. Brain Res Bull 2003;59(6):533-43
   PubMed Web of Science ®Google Scholar
• Bragdon EE, Light KC, Costello NL, Group differences in pain modulation: pain-free women compared to pain-free men and to women with TMD. Pain 2002;96(3):227-37
   PubMed Web of Science ®Google Scholar
• Bendtsen L. Central sensitization in tension-type headache–possible pathophysiological mechanisms. Cephalalgia 2000;20(5):486-508
   PubMed Web of Science ®Google Scholar
• Papageorgiou AC, Silman AJ, Macfarlane GJ. Chronic widespread pain in the population: a seven year follow up study. Ann Rheum Dis 2002;61(12):1071-4
   PubMed Web of Science ®Google Scholar
• Ablin J, Neumann L, Buskila D. Pathogenesis of fibromyalgia–a review. Joint Bone Spine 2008;75(3):273-9
   PubMed Web of Science ®Google Scholar
• Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol 2003;17(4):685-701
   PubMed Web of Science ®Google Scholar
• Giesecke T, Gracely RH, Grant MA, Evidence of augmented central pain processing in idiopathic chronic low back pain. Arthritis Rheum 2004;50(2):613-23
   PubMed Web of Science ®Google Scholar
• Ablin JN, Buskila D. Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs 2008;13(1):53-62
   PubMed Web of Science ®Google Scholar
• Carville SF, Arendt-Nielsen S, Bliddal H, EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008;67(4):536-41
   PubMed Web of Science ®Google Scholar
• Briley M. Drugs to treat fibromyalgia–the transatlantic difference. Curr Opin Investig Drugs 2010;11(1):16-8
   PubMed Web of Science ®Google Scholar
• Wolfe F, Ross K, Anderson J, The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38(1):19-28
   PubMed Web of Science ®Google Scholar
• Lempp HK, Hatch SL, Carville SF, Choy EH. Patients' experiences of living with and receiving treatment for fibromyalgia syndrome: a qualitative study. BMC Musculoskelet Disord 2009;10:124
   PubMed Web of Science ®Google Scholar
• Annemans L, Le Lay K, Taieb C. Societal and patient burden of fibromyalgia syndrome. Pharmacoeconomics 2009;27(7):547-59
   PubMed Web of Science ®Google Scholar
• Spaeth M. Epidemiology, costs, and the economic burden of fibromyalgia. Arthritis Res Ther 2009;11(3):117
   PubMed Web of Science ®Google Scholar
• Arendt-Nielsen L, Graven-Nielsen T. Central sensitization in fibromyalgia and other musculoskeletal disorders. Curr Pain Headache Rep 2003;7(5):355-61
   PubMedGoogle Scholar
• Desmeules JA, Cedraschi C, Rapiti E, Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum 2003;48(5):1420-9
   PubMed Web of Science ®Google Scholar
• Yunus MB. Role of central sensitization in symptoms beyond muscle pain, and the evaluation of a patient with widespread pain. Best Pract Res Clin Rheumatol 2007;21(3):481-97
   PubMed Web of Science ®Google Scholar
• Martinez-Lavin M, Hermosillo AG. Autonomic nervous system dysfunction may explain the multisystem features of fibromyalgia [editorial, comment]. Semin Arthritis Rheum 2000;29(4):197-9
   PubMed Web of Science ®Google Scholar
• Arnold LM, Crofford LJ, Martin SA, The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia. Pain Med 2007;8(8):633-8
   PubMed Web of Science ®Google Scholar
• Jaeschke R, Adachi J, Guyatt G, Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials. J Rheumatol 1991;18(3):447-51
   PubMed Web of Science ®Google Scholar
• Scudds RA, McCain GA, Rollman GB, Harth M. Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline. J Rheumatol Suppl 1989;19:98-103
   PubMedGoogle Scholar
• Goldenberg D, Mayskiy M, Mossey C, A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996;39(11):1852-9
   PubMed Web of Science ®Google Scholar
• Johnson SP. Fluoxetine and amitriptyline in the treatment of fibromyalgia. J Fam Pract 1997;44(2):128-30
   PubMedGoogle Scholar
• Arnold LM, Hess EV, Hudson JI, A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002;112(3):191-7
   PubMed Web of Science ®Google Scholar
• Geller SA. Treatment of fibrositis with fluoxetine hydrochloride (Prozac). Am J Med 1989;87(5):594-5
   PubMed Web of Science ®Google Scholar
• Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994;23(5):255-9
   PubMed Web of Science ®Google Scholar
• Norregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995;61(3):445-9
   PubMed Web of Science ®Google Scholar
• Anderberg UM, Marteinsdottir I, Von Knorring L. Citalopram in patients with fibromyalgia–a randomized, double-blind, placebo-controlled study. Eur J Pain 2000;4(1):27-35
   PubMed Web of Science ®Google Scholar
• Patkar AA, Masand PS, Krulewicz S, A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. Am J Med 2007;120(5):448-54
   PubMed Web of Science ®Google Scholar
• Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 2003;114(7):537-45
   PubMed Web of Science ®Google Scholar
• Biasi G, Manca S, Manganelli S, Marcolongo R. Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. Int J Clin Pharmacol Res 1998;18(1):13-9
   PubMedGoogle Scholar
• Russell IJ, Kamin M, Bennett RM, Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol 2000;6:250-7
   PubMed Web of Science ®Google Scholar
• Russell IJ, Crofford LJ, Leon T, The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome. Sleep Med 2009;10(6):604-10
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Herman BK, Schweizer E, Mandel FS. The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia. Int Clin Psychopharmacol 2009;24(4):214-22
   PubMed Web of Science ®Google Scholar
• Briley M. Drugs to treat fibromyalgia–the transatlantic difference. Curr Opin Investig Drugs 2010;11(1):16-8
   PubMed Web of Science ®Google Scholar
• Arnold LM, Lu Y, Crofford LJ, A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50(9):2974-84
   PubMed Web of Science ®Google Scholar
• Arnold LM. Duloxetine and other antidepressants in the treatment of patients with fibromyalgia. Pain Med 2007;8(Suppl 2):S63-S74
   PubMedGoogle Scholar
• Russell IJ, Mease PJ, Smith TR, Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136(3):432-44
   Google Scholar
• Gendreau RM, Thorn MD, Gendreau JF, The efficacy of milnacipran in fibromyalgia. J Rheumatol 2005;32(10):1975-85
   Google Scholar
• Vitton O, Gendreau M, Gendreau J, A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004;19(Suppl 1):S27-S35
   PubMedGoogle Scholar
• Branco JC, Zachrisson O, Perrot S, Mainguy Y. A European Multicenter Randomized Double-blind Placebo-controlled Monotherapy Clinical Trial of milnacipran in the treatment of fibromyalgia. J Rheumatol 2010;37(4):851-9
   Google Scholar
• Agargun MY, Tekeoglu I, Gunes A, Sleep quality and pain threshold in patients with fibromyalgia. Compr Psychiatry 1999;40(3):226-8
   PubMed Web of Science ®Google Scholar
• Branco J, Atalaia A, Paiva T. Sleep cycles and alpha-delta sleep in fibromyalgia syndrome. J Rheumatol 1994;21(6):1113-7
   PubMed Web of Science ®Google Scholar
• Hamilton NA, Affleck G, Tennen H, Fibromyalgia: the role of sleep in affect and in negative event reactivity and recovery. Health Psychol 2008;27(4):490-7
   PubMed Web of Science ®Google Scholar
• Harding SM. Sleep in fibromyalgia patients: subjective and objective findings. Am J Med Sci 1998;315(6):367-76
   PubMed Web of Science ®Google Scholar
• Korszun A. Sleep and circadian rhythm disorders in fibromyalgia. Curr Rheumatol Rep 2000;2(2):124-30
   PubMedGoogle Scholar
• Moldofsky H, Scarisbrick P, England R, Smythe H. Musculosketal symptoms and non-REM sleep disturbance in patients with “fibrositis syndrome” and healthy subjects. Psychosom Med 1975;37(4):341-51
   PubMed Web of Science ®Google Scholar
• Moldofsky H. The significance of the sleeping-waking brain for the understanding of widespread musculoskeletal pain and fatigue in fibromyalgia syndrome and allied syndromes. Joint Bone Spine 2008;75(4):397-402
   PubMed Web of Science ®Google Scholar
• Drewes AM, Nielsen KD, Jennum PJ, Andreasen A. Alpha intrusion of deeper sleep stages in fibromyalgia–A study based on quantitative frequency analysis. Scand J Rheumato 1992;94S:40
   Google Scholar
• May KP, West SG, Baker MR, Everett DW. Sleep apnea in male patients with the fibromyalgia syndrome. Am J Med 1993;94(5):505-8
   PubMed Web of Science ®Google Scholar
• Gold AR, Dipalo F, Gold MS, Broderick J. Inspiratory airflow dynamics during sleep in women with fibromyalgia. Sleep 2004;27(3):459-66
   PubMed Web of Science ®Google Scholar
• Smith MT, Wickwire EM, Grace EG, Sleep disorders and their association with laboratory pain sensitivity in temporomandibular joint disorder. Sleep 2009;32(6):779-90
   PubMed Web of Science ®Google Scholar
• Edwards RR, Grace E, Peterson S, Sleep continuity and architecture: associations with pain-inhibitory processes in patients with temporomandibular joint disorder. Eur J Pain 2009;13(10):1043-7
   PubMed Web of Science ®Google Scholar
• Nishishinya B, Urrutia G, Walitt B, Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy. Rheumatology (Oxford) 2008;47(12):1741-6
   PubMed Web of Science ®Google Scholar
• Carette S, Oakson G, Guimont C, Steriade M. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis Rheum 1995;38(9):1211-7
   PubMed Web of Science ®Google Scholar
• Krystal AD, Walsh JK, Laska E, Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26(7):793-9
   PubMed Web of Science ®Google Scholar
• Scharf M. Eszopiclone for the treatment of insomnia. Expert Opin Pharmacother 2006;7(3):345-56
   PubMed Web of Science ®Google Scholar
• Sepracor I. Eszopiclone in the treatment of insomnia and fibromyalgia. Available from: ClinicalTrials.gov. 2 March 2010
   Google Scholar
• Citera G, Arias MA, Maldonado-Cocco JA, The effect of melatonin in patients with fibromyalgia: a pilot study. Clin Rheumatol 2000;19(1):9-13
   PubMed Web of Science ®Google Scholar
• Wikner J, Hirsch U, Wetterberg L, Rojdmark S. Fibromyalgia–a syndrome associated with decreased nocturnal melatonin secretion. Clin Endocrinol (Oxf) 1998;49(2):179-83
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Pandi-Perumal SR, Spence DW, Potential use of melatonergic drugs in analgesia: mechanisms of action. Brain Res Bull 2010;81(4-5):362-71
   PubMed Web of Science ®Google Scholar
• Pandi-Perumal SR, Srinivasan V, Spence DW, Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther 2009;26(6):613-26
   PubMed Web of Science ®Google Scholar
• Scharf MB, Hauck M, Stover R, Effect of gamma-hydroxybutyrate on pain, fatigue, and the alpha sleep anomaly in patients with fibromyalgia. Preliminary report. J Rheumatol 1998;25(10):1986-90
   PubMed Web of Science ®Google Scholar
• Scharf MB, Baumann M, Berkowitz DV. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol 2003;30(5):1070-4
   PubMed Web of Science ®Google Scholar
• Russell IJ, Perkins AT, Michalek JE. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum 2009;60(1):299-309
   PubMed Web of Science ®Google Scholar
• Jazz. Jazz Pharmaceuticals and UCB Announce Positive phase III results for sodium oxybate JZP-6. In fibromyalgia. Jazz Pharmaceuticals, Inc Press release; 2010
   Google Scholar
• Fink K, Dooley DJ, Meder WP, Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002;42(2):229-36
   PubMed Web of Science ®Google Scholar
• Bian F, Li Z, Offord J, Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice. Brain Res 2006;1075(1):68-80
   PubMed Web of Science ®Google Scholar
• Arnold LM, Crofford LJ, Martin SA, The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia. Pain Med 2007;8(8):633-8
   PubMed Web of Science ®Google Scholar
• Crofford LJ, Rowbotham MC, Mease PJ, Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52(4):1264-73
   PubMed Web of Science ®Google Scholar
• Mease PJ, Russell IJ, Arnold LM, A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;35(3):502-14
   PubMed Web of Science ®Google Scholar
• Arnold LM, Goldenberg DL, Stanford SB, Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007;56(4):1336-44
   PubMed Web of Science ®Google Scholar
• Pollack MH, Roy-Byrne PP, Van Ameringen M, The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry 2005;66(11):1401-8
   PubMed Web of Science ®Google Scholar
• Dib JG. Focus on topiramate in neuropathic pain. Curr Med Res Opin 2004;20(12):1857-61
   PubMed Web of Science ®Google Scholar
• Garcia-Campayo J, Sanz-Carrillo C. Topiramate as a treatment for pain in multisomatoform disorder patients: an open trial. Gen Hosp Psychiatry 2002;24(6):417-21
   PubMed Web of Science ®Google Scholar
• UCB, Inc. Levetiracetam for Treatment of Pain Associated With Fibromyalgia. Available from: ClinicalTrials.gov. 2 August 2008
   Google Scholar
• Eisai, Inc. Zonisamide for Fibromyalgia & Migraine. Available from: ClinicalTrials.gov. 11 November 2008
   Google Scholar
• UCB I. Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome. Available from: ClinicalTrials.gov. 23 December 2009
   Google Scholar
• Lynch BA, Lambeng N, Nocka K, The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004;101(26):9861-6
   PubMed Web of Science ®Google Scholar
• Rossi S, Mataluni G, Codeca C, Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study. Eur J Neurol 2009;16(3):360-6
   PubMed Web of Science ®Google Scholar
• Hamza MS, Anderson DG, Snyder JW, Effectiveness of levetiracetam in the treatment of lumbar radiculopathy: an open-label prospective cohort study. PMR 2009;1(4):335-9
   PubMedGoogle Scholar
• Finnerup NB, Grydehoj J, Bing J, Levetiracetam in spinal cord injury pain: a randomized controlled trial. Spinal Cord 2009;47(12):861-7
   PubMed Web of Science ®Google Scholar
• Vilholm OJ, Cold S, Rasmussen L, Sindrup SH. Effect of levetiracetam on the postmastectomy pain syndrome. Eur J Neurol 2008;15(8):851-7
   PubMed Web of Science ®Google Scholar
• Ueda Y, Doi T, Tokumaru J, Willmore LJ. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res 2003;116(1-2):1-6
   PubMedGoogle Scholar
• Tanabe M, Sakaue A, Takasu K, Centrally mediated antihyperalgesic and antiallodynic effects of zonisamide following partial nerve injury in the mouse. Naunyn Schmiedebergs Arch Pharmacol 2005;372(2):107-14
   PubMed Web of Science ®Google Scholar
• Hasegawa H. Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: a retrospective, open label, uncontrolled study in a VA hospital. Curr Med Res Opin 2004;20(5):577-80
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Hashimoto K, Tsuji S. Successful use of zonisamide for central poststroke pain. J Pain 2004;5(3):192-4
   PubMed Web of Science ®Google Scholar
• Errington AC, Stohr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008;73(1):157-69
   PubMed Web of Science ®Google Scholar
• Shaibani A, Fares S, Selam JL, Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial. J Pain 2009;10(8):818-28
   PubMed Web of Science ®Google Scholar
• Beyreuther BK, Geis C, Stohr T, Sommer C. Antihyperalgesic efficacy of lacosamide in a rat model for muscle pain induced by TNF. Neuropharmacology 2007;52(5):1312-7
   PubMed Web of Science ®Google Scholar
• UCB I. Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome. Available from: ClinicalTrials.gov. 23 December 2009
   Google Scholar
• Malt EA, Olafsson S, Aakvaag A, Altered dopamine D2 receptor function in fibromyalgia patients: a neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls. J Affect Disord 2003;75(1):77-82
   PubMed Web of Science ®Google Scholar
• Wood PB, Patterson JC, Sunderland JJ, Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: a pilot study. J Pain 2007;8(1):51-8
   PubMed Web of Science ®Google Scholar
• Wood PB, Schweinhardt P, Jaeger E, Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci 2007;25(12):3576-82
   PubMed Web of Science ®Google Scholar
• Buskila D, Cohen H, Neumann L, Ebstein RP. An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry 2004;9(8):730-1
   PubMed Web of Science ®Google Scholar
• Nagakura Y, Oe T, Aoki T, Matsuoka N. Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia. Pain 2009;146(1-2):26-33
   PubMed Web of Science ®Google Scholar
• Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 2005;52(8):2495-505
   PubMed Web of Science ®Google Scholar
• Bliwise DL, Freeman A, Ingram CD, Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. Sleep Med 2005;6(2):141-7
   PubMed Web of Science ®Google Scholar
• Holman AJ. Ropinirole, open preliminary observations of a dopamine agonist for refractory fibromyalgia. J Clin Rheumatol 2003;9(4):277-9
   PubMed Web of Science ®Google Scholar
• GSK. A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety and efficacy of controlled-release ropinirole (CR. (1-24mg. administered once daily for 12 weeks in subjects with fibromyalgia. GlaxoSmithKline. 2005. 27 Februrary 2010
   Google Scholar
• Distler O, Eich W, Dokoupilova E, Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2010;62(1):291-300
   PubMed Web of Science ®Google Scholar
• Chen JJ, Swope DM, Dashtipour K, Lyons KE. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease. Pharmacotherapy 2009;29(12):1452-67
   PubMed Web of Science ®Google Scholar
• Sixel-Doring F, Trenkwalder C. Rotigotine transdermal delivery for the treatment of restless legs syndrome. Expert Opin Pharmacother 2010;11(4):649-56
   PubMed Web of Science ®Google Scholar
• UCB I. he Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults. (SP888). Available from: ClinicalTrials.gov. 5 January 2010
   Google Scholar
• UCB, Inc. Phase IIa study: rotigotine in fibromyalgia syndrome. UCB, Inc. Press Release; 2010
   Google Scholar
• Wood PB, Holman AJ. An elephant among us: the role of dopamine in the pathophysiology of fibromyalgia. J Rheumatol 2009;36(2):221-4
   PubMed Web of Science ®Google Scholar
• Carville SF, Arendt-Nielsen S, Bliddal H, EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008;67(4):536-41
   PubMed Web of Science ®Google Scholar
• Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett 2008;29(2):192-200
   PubMed Web of Science ®Google Scholar
• Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag 2008;4(1):245-59
   PubMedGoogle Scholar
• Schley M, Legler A, Skopp G, Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Curr Med Res Opin 2006;22(7):1269-76
   PubMed Web of Science ®Google Scholar
• Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008;9(2):164-73
   PubMed Web of Science ®Google Scholar
• Ware MA, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 2010;110(2):604-10
   PubMed Web of Science ®Google Scholar
• Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008;9(2):164-73
   PubMed Web of Science ®Google Scholar
• Bagge E, Bengtsson BA, Carlsson L, Carlsson J. Low growth hormone secretion in patients with fibromyalgia–a preliminary report on 10 patients and 10 controls. J Rheumatol 1998;25(1):145-8
   PubMed Web of Science ®Google Scholar
• Bennett RM, Clark SC, Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 1998;104(3):227-31
   PubMed Web of Science ®Google Scholar
• Bennet R. Efficacy and safety of an oral growth hormone drug in the treatment of fibromyalgia. Available from: ClinicalTrials.gov. 2010
   Google Scholar
• Jones KD, Burckhardt CS, Deodhar AA, A six-month randomized controlled trial of exercise and pyridostigmine in the treatment of fibromyalgia. Arthritis Rheum 2008;58(2):612-22
   PubMed Web of Science ®Google Scholar
• Dougherty PM, Palecek J, Paleckova V, The role of NMDA and non-NMDA excitatory amino acid receptors in the excitation of primate spinothalamic tract neurons by mechanical, chemical, thermal, and electrical stimuli. J Neurosci 1992;12(8):3025-41
   PubMed Web of Science ®Google Scholar
• Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000;288(5472):1765-9
   PubMed Web of Science ®Google Scholar
• Staud R, Vierck CJ, Robinson ME, Price DD. Effects of the N-methyl-D-aspartate receptor antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal control subjects. J Pain 2005;6(5):323-32
   PubMed Web of Science ®Google Scholar
• Cohen SP, Verdolin MH, Chang AS, The intravenous ketamine test predicts subsequent response to an oral dextromethorphan treatment regimen in fibromyalgia patients. J Pain 2006;7(6):391-8
   PubMed Web of Science ®Google Scholar
• Graven-Nielsen T, Aspegren KS, Henriksson KG, Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 2000;85(3):483-91
   PubMed Web of Science ®Google Scholar
• Wood PB. A reconsideration of the relevance of systemic low-dose ketamine to the pathophysiology of fibromyalgia. J Pain 2006;7(9):611-4
   PubMed Web of Science ®Google Scholar
• Guedj E, Cammilleri S, Colavolpe C, Predictive value of brain perfusion SPECT for ketamine response in hyperalgesic fibromyalgia. Eur J Nucl Med Mol Imaging 2007;34(8):1274-9
   PubMed Web of Science ®Google Scholar
• Harris RE, Clauw DJ, Scott DJ, Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci 2007;27(37):10000-6
   PubMed Web of Science ®Google Scholar
• Panerai AE, Vecchiet J, Panzeri P, Peripheral blood mononuclear cell beta-endorphin concentration is decreased in chronic fatigue syndrome and fibromyalgia but not in depression: preliminary report. Clin J Pain 2002;18(4):270-3
   PubMed Web of Science ®Google Scholar
• Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med 2009;10(4):663-72
   PubMed Web of Science ®Google Scholar
• Younger JW, Zautra AJ, Cummins ET. Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology. PLoS One 2009;4(4):e5180
   PubMedGoogle Scholar
• Ishizuka T, Murakami M, Yamatodani A. Involvement of central histaminergic systems in modafinil-induced but not methylphenidate-induced increases in locomotor activity in rats. Eur J Pharmacol 2008;578(2-3):209-15
   PubMed Web of Science ®Google Scholar
• Czeisler CA, Walsh JK, Roth T, Modafinil for excessive sleepiness associated with shift-work sleep disorder. N Engl J Med 2005;353(5):476-86
   PubMed Web of Science ®Google Scholar
• Disdier P, Genton P, Milandre C, Fibrositis syndrome and narcolepsy. J Rheumatol 1993;20(5):888-9
   PubMed Web of Science ®Google Scholar
• Schwartz TL, Rayancha S, Rashid A, Modafinil treatment for fatigue associated with fibromyalgia. J Clin Rheumatol 2007;13(1):52
   PubMed Web of Science ®Google Scholar
• Schaller JL, Behar D. Modafinil in fibromyalgia treatment. J Neuropsychiatry Clin Neurosci 2001;13(4):530-1
   PubMed Web of Science ®Google Scholar
• Schwartz T. Armodafinil for fibromyalgia fatigue. Available from: ClinicalTrials.gov. 28 Februrary 2010
   Google Scholar
• Schwartz T. An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue. Available from: ClinicalTrials.gov. 28 Februrary 2010
   Google Scholar
• Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000;68(1):29-39
   PubMed Web of Science ®Google Scholar
• Hidalgo J, Rico-Villademoros F, Calandre EP. An open-label study of quetiapine in the treatment of fibromyalgia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(1):71-7
   PubMed Web of Science ®Google Scholar
• Calandre EP, Morillas-Arques P, Rodriguez-Lopez CM, Pregabalin augmentation of quetiapine therapy in the treatment of fibromyalgia: an open-label, prospective trial. Pharmacopsychiatry 2007;40(2):68-71
   PubMed Web of Science ®Google Scholar
• Moore N. Quetiapine compared with placebo in the management of fibromyalgia. Available from: ClinicalTrial.gov. 28 Februrary 2010
   Google Scholar
• Calandre E. Comparative efficacy and tolerability of quetiapine xr and amitriptyline in the treatment of fibromyalgia. Available from: ClinicalTrial.gov. 28 Februrary 2010
   Google Scholar
• McIntyre A. A Study of quetiapine fumarate sustained release in major depression with comorbid fibromyalgia syndrome. Available from: ClinicalTrial.gov. 28 Februrary 2010
   Google Scholar
• Vaeroy H, Helle R, Forre O, Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988;32(1):21-6
   PubMed Web of Science ®Google Scholar
• Russell IJ, Orr MD, Littman B, Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994;37(11):1593-601
   PubMed Web of Science ®Google Scholar
• Quartara L, Maggi CA. The tachykinin NK1 receptor. Part II: distribution and pathophysiological roles. Neuropeptides 1998;32(1):1-49
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Apornwirat W, Shaharyar A, Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol 2009;27(32):5363-9
   PubMed Web of Science ®Google Scholar
• GSK. GW679769 in fibromyalgia. Available from: ClinicalTrials.gov. 1 March 2010
   Google Scholar
• Vargas-Alarcon G, Fragoso JM, Cruz-Robles D, Catechol-O-methyltransferase gene haplotypes in Mexican and Spanish patients with fibromyalgia. Arthritis Res Ther 2007;9(5):R110
   PubMedGoogle Scholar
• van Meurs JB, Uitterlinden AG, Stolk L, A functional polymorphism in the catechol-O-methyltransferase gene is associated with osteoarthritis-related pain. Arthritis Rheum 2009;60(2):628-9
   PubMed Web of Science ®Google Scholar
• Clauw DJ, Witter J. Pain and rheumatology: thinking outside the joint. Arthritis Rheum 2009;60(2):321-4
   PubMed Web of Science ®Google Scholar
• Wolfe F, Smythe HA, Yunus MB, The American college of rheumatology 1990 criteria for the classification of fibromyalgia. report of the multicenter criteria committee. Arthritis Rheum 1990;33(2):160-72
   PubMed Web of Science ®Google Scholar
• Wilke WS. New developments in the diagnosis of fibromyalgia syndrome: say goodbye to tender points? Cleve Clin J Med 2009;76(6):345-52
   PubMed Web of Science ®Google Scholar
• Harth M, Nielson WR. The fibromyalgia tender points: use them or lose them? A brief review of the controversy. J Rheumatol 2007;34(5):914-22
   PubMed Web of Science ®Google Scholar